A drug that kills cancer cells through an entirely different mechanism than Enhertu achieved a 50% response rate Monday in HER2-positive breast cancer patients who had already failed trastuzumab deruxtecan — a setting where no standard treatment currently exists and approved alternatives have returned response rates of zero to 3.7%.

LigaChem Biosciences and its partner Iksuda Therapeutics announced the interim Phase 1 data for IKS014, also known as caxmotabart entudotin, on November 2, 2026. Five of 10 evaluable patients with HER2-positive metastatic breast cancer who had previously received Enhertu achieved a partial response to IKS014 monotherapy. One of those responses has lasted more than 18 months. A sixth patient had stable disease. The patients had received a median of six prior lines of therapy — a reflection of how heavily pretreated this population is — with a range from two to 12 prior regimens.

Updated Phase 1 data, incorporating additional patients enrolled since the April 2026 data cutoff used for this analysis, will be presented at the San Antonio Breast Cancer Symposium (SABCS) on December 9, 2026.

The Gap Enhertu Left Behind

Enhertu (trastuzumab deruxtecan), developed by AstraZeneca and Daiichi Sankyo, is now approved in more than 100 countries for HER2-positive metastatic breast cancer patients who have received a prior anti-HER2 regimen. It has become the dominant second-line standard of care and is increasingly moving into earlier treatment settings. As Enhertu’s reach expands, so does the number of patients who will eventually progress on it — and for those patients, there is currently no established next step.

The data from attempts to treat this population with existing agents paints a stark picture. A retrospective study from MD Anderson Cancer Center found that Kadcyla (trastuzumab emtansine) — Genentech’s older HER2-targeted antibody-drug conjugate — produced zero responses in 21 patients who had previously received Enhertu, with a median progression-free survival of just 2.2 months.

The SATEEN trial, a prospective study combining Trodelvy (sacituzumab govitecan) with trastuzumab in post-Enhertu HER2-positive breast cancer patients, fared only marginally better: one of 27 patients responded (3.7% ORR), the trial was stopped early for missing its efficacy threshold, and one patient died from neutropenic sepsis.

Paolo Tarantino, MD, PhD, of Dana-Farber Cancer Institute and SATEEN’s lead investigator, has stated that “no prospective data currently exist to guide treatment selection following progression on [trastuzumab deruxtecan]” and that the SATEEN results “help clarify treatment expectations after T-DXd and reinforce the importance of developing new approaches” — a polite way of saying the combination failed and the problem remains unsolved.

Same Antibody, Different Cellular Kill Switch: Why Payload Class Is the Key Variable

The failure of Kadcyla and the near-failure of SATEEN are not accidents. Both drugs share a key characteristic with Enhertu that IKS014 does not.

Enhertu delivers its payload — a compound called deruxtecan, or DXd — by binding to the HER2 receptor on cancer cells. Once internalized, DXd inhibits an enzyme called topoisomerase I (TOP1), which cancer cells use to unwind DNA during replication. When TOP1 is blocked, DNA replication stalls and the cell dies.

Trodelvy, used in the SATEEN trial, uses the same class of payload — a topoisomerase I inhibitor called SN-38. When a patient’s cancer develops resistance to Enhertu through changes that reduce TOP1 sensitivity or upregulate DNA-repair pathways, that same resistance mechanism is already in place when Trodelvy arrives. This is cross-resistance: two drugs from different companies hitting the same molecular target find the same locked door.

IKS014 carries a fundamentally different payload: monomethyl auristatin F, or MMAF. MMAF does not touch topoisomerase at all. Instead, it binds to tubulin, the protein subunit that assembles into the microtubules cancer cells need to physically pull duplicated chromosomes apart during cell division. Without functional microtubules, cells arrest at the G2/M phase of the cell cycle and die through a completely separate pathway. A cell that has learned to resist a topoisomerase I inhibitor has no intrinsic head start against a microtubule disruptor.

This is not an abstract distinction. It is, based on IKS014’s Phase 1 data, a clinically meaningful one. A 50% response rate against a backdrop of zero to 3.7% responses from TOP1i-based approaches in the same patient population is the strongest signal yet that payload-class sequencing — not just HER2 targeting — is the organizing principle that will govern post-Enhertu treatment strategy.

How IKS014 Works: Beta-Glucuronidase Linker, MMAF, and the Architecture of Precision Delivery

IKS014 was not designed by attaching MMAF to trastuzumab with the nearest available chemistry. Its architecture is the result of LigaChem Biosciences’ proprietary ConjuALL platform, and three specific engineering choices distinguish it from earlier MMAF-based drugs and from Enhertu itself.

Payload selection: MMAF vs. MMAE. MMAF and its close relative MMAE (monomethyl auristatin E, used in Seattle Genetics’ Adcetris) both inhibit tubulin polymerization, but they behave differently once released from the antibody. MMAE is membrane-permeable — it can escape the tumor cell it entered and kill neighboring cells regardless of whether those cells express HER2. This bystander effect amplifies potency but also increases systemic toxicity, particularly peripheral neuropathy. MMAF carries a charged molecule that keeps it membrane-impermeable and cell-confined, reducing off-target exposure. For a drug intended to be used in patients who have already received multiple prior therapies, that reduction in systemic toxicity is a design priority.

The beta-glucuronidase linker. IKS014 connects MMAF to trastuzumab via a beta-glucuronide linker — a chemical that remains stable in the bloodstream but is cleaved specifically by an enzyme called beta-glucuronidase. This enzyme is overexpressed in tumor lysosomes (the cellular organelles where internalized antibody-drug conjugates are broken down) and in the tumor microenvironment, including necrotic regions, at levels substantially higher than in healthy tissues, including the corneal epithelium. This spatial selectivity provides an additional layer of tumor targeting beyond the antibody-antigen interaction itself.

The clinical significance of this linker design may explain a notable absence in IKS014’s Phase 1 safety data. Belantamab mafodotin (Blenrep), a multiple myeloma drug that also uses MMAF but couples it via a non-selective maleimide linker, caused grade 3 or higher corneal epitheliopathy (keratopathy) in 45% of patients in its registration trial — a toxicity severe enough to require detailed ophthalmology monitoring and to limit the drug’s uptake. In the IKS014 Phase 1 covering 105 patients, no grade 3 keratitis was observed. Dry eye was reported in 55% of patients and grade 1-2 keratitis in 32%, but both are manageable without dose interruption in most cases.

Site-specific conjugation at DAR=2. IKS014’s drug-to-antibody ratio — the number of MMAF molecules attached per trastuzumab antibody — is exactly 2. This is intentionally low compared to Kadcyla (average DAR approximately 3.5) and dramatically lower than Enhertu (DAR=8). Higher DAR loads more drug per antibody but increases the hydrophobicity of the resulting conjugate, causing aggregation, rapid clearance from the bloodstream, and broader off-target distribution. ConjuALL achieves site-specific conjugation — meaning every MMAF molecule attaches at a defined, controlled position on the antibody — producing a homogeneous product with consistent pharmacokinetics. The low DAR is paired with MMAF’s high intrinsic potency, with the beta-glucuronidase linker ensuring that the payload reaches the tumor’s own enzyme-rich lysosomal compartment before it is released.

What the Phase 1 Numbers Show — and What They Cannot Prove Yet

Fifty percent is a striking number. It requires context.

The 10 evaluable patients in the post-Enhertu cohort represent a small subset of the 105 patients enrolled in Part 1 (dose escalation, 71 patients) and Part 2 (dose expansion, 34 patients) of Phase 1 trial NCT05872295, conducted at sites in Australia, the United States, New Zealand, and Singapore. The recommended Phase 2 dose (RP2D) was established at 105 mg/m2. With n=10, the 95% confidence interval around a 50% ORR is approximately +/-31 percentage points — statistically compatible with a true response rate anywhere from roughly 19% to 81%. This is a Phase 1 signal, not a Phase 3 confirmation.

The data cutoff for this analysis was April 2026. Additional patients have since been enrolled in the post-Enhertu cohort, and their data will be included in the SABCS December 9 presentation. If the updated data — with a larger denominator — sustains a response rate meaningfully above the zero-to-3.7% comparator range, it will substantially strengthen the case for a registrational trial in this indication.

Grade 3 or higher treatment-related adverse events occurred in 15.2% of patients across the full 105-patient safety population. No grade 5 (fatal) treatment-related adverse events were reported. No high-grade interstitial lung disease or pneumonitis — a class effect that has required careful monitoring for Enhertu, where it has occurred in roughly 14-15% of patients (grade 3 or higher in 3%) — was observed with IKS014.

LigaChem describes this as the highest reported ORR for a HER2 ADC monotherapy in Enhertu-pretreated HER2-positive breast cancer. That claim cannot be independently adjudicated from published literature at this writing, but it is consistent with the comparator data reviewed above.

Commercial Structure and the China Rights Question

IKS014 was invented by LigaChem Biosciences, a KOSDAQ-listed biotech founded in 2006 and headquartered in Daejeon, South Korea. In January 2022, LigaChem granted Iksuda Therapeutics — a company founded in Newcastle, England, to bring the drug into clinical development — exclusive worldwide rights to IKS014 for all indications outside Greater China and South Korea. The deal was structured with potential milestone and royalty payments that could reach approximately 1.12 trillion yen (approximately $7.5 billion USD at current exchange rates) in total value, with $50 million paid upfront. LigaChem subsequently invested $25 million in Iksuda and holds an equity stake option of up to 73.9% of Iksuda shares through an investor agreement with existing investors.

Greater China rights are held by Fosun Pharma, which is running a separate Phase 3 clinical trial of IKS014 under the name FS-1502 in China, comparing the drug against Kadcyla in HER2-positive breast cancer. Fosun Pharma is a Chinese company subject to China’s National Intelligence Law (2017), which requires all Chinese organizations to support, assist, and cooperate with national intelligence work on request. This legal obligation applies to Fosun’s operations and to data collected under its Chinese clinical trials — it does not govern Iksuda’s global (ex-China) development program, but readers in US pharmaceutical and investment contexts should note that Fosun’s access to Chinese patient data from FS-1502 is subject to these provisions.

IKS014’s ConjuALL platform also won recognition at the World ADC Awards (2025) as both the “Most Promising ADC to Watch” and for the ConjuALL platform category, ahead of candidates from Pfizer and Mersana Therapeutics.

Where the Data Heads Next: SABCS December 9 and Beyond

Iksuda will present updated IKS014 Phase 1 data at the San Antonio Breast Cancer Symposium, which will run December 8-11, 2026 at the Henry B. Gonzalez Convention Center in San Antonio, Texas. The HER2 Poster Spotlight session is scheduled for 7:00 AM-8:30 AM CST (8:00 AM-9:30 AM ET) on December 9, 2026 in Room 301 ABC. The updated data will include patients enrolled after the April 2026 cutoff and is expected to provide a clearer picture of IKS014’s response rate in the post-Enhertu cohort with a larger sample.

Iksuda has previously presented Phase 1 data at ESMO 2025 and at ASCO GI 2026, where the drug showed a 50% ORR including one complete response in 10 evaluable HER2-positive esophageal cancer patients, suggesting the post-Enhertu activity in breast cancer may reflect a broader HER2-tumor mechanism rather than a breast-cancer-specific effect.

A pivotal Phase 2 or Phase 3 trial in the post-Enhertu breast cancer setting has not yet been announced. The SABCS data presentation will be a key decision point for whether that path opens.

Currency conversions in this article are approximate, based on mid-market exchange rates (approximately 150.1 JPY/USD) as of November 2, 2026, and are subject to change.

Frequently Asked Questions

Why does IKS014 work in patients whose cancer stopped responding to Enhertu?

Enhertu kills cancer cells using a topoisomerase I inhibitor payload called deruxtecan. Topoisomerase I is an enzyme cancer cells use to unwind DNA during replication; blocking it causes lethal DNA damage. When a HER2-positive tumor develops resistance to Enhertu, it often does so by altering this topoisomerase pathway — which also explains why other topoisomerase I inhibitors such as Trodelvy (used in the SATEEN trial) produced nearly no responses in the same patient population. IKS014 uses an entirely different payload — MMAF, a microtubule disruptor — that targets microtubule protein machinery responsible for physically separating chromosomes during cell division. A tumor that has learned to resist a topoisomerase inhibitor has no pre-existing resistance to a microtubule inhibitor. The 50% response rate in the Phase 1 cohort is the clearest signal yet that this mechanism switch can overcome the cross-resistance pattern.

What is an antibody-drug conjugate (ADC), and how does IKS014 differ from other ADCs like Kadcyla and Enhertu?

An antibody-drug conjugate attaches a cancer-killing drug payload to an antibody that recognizes a specific protein on tumor cells — in this case, HER2. The antibody acts as a delivery vehicle, binding to HER2-expressing cancer cells, getting pulled inside the cell, and then releasing the toxic payload intracellularly. Kadcyla (T-DM1) uses an emtansine payload — also a microtubule disruptor, but from a different drug class (maytansinoid) and coupled randomly to the antibody at multiple sites, producing a heterogeneous mixture of conjugates. Enhertu uses a deruxtecan payload (topoisomerase I inhibitor) with a high drug-to-antibody ratio (DAR=8), loading eight drug molecules per antibody. IKS014 uses MMAF coupled via a tumor-enzyme-activated beta-glucuronide linker at a precisely controlled DAR=2, producing a homogeneous conjugate whose payload releases selectively in tumor lysosomes — the design choice that appears to reduce the severe eye toxicity seen with the earlier MMAF-based drug Blenrep.

When will IKS014 be available as a treatment option?

IKS014 is currently in Phase 1 clinical trials (NCT05872295) and is not approved for any indication. Phase 1 trials are primarily designed to establish safety and dosing, not to prove efficacy — the 50% ORR result is a preliminary signal that warrants further investigation in a larger, randomized trial. The December 9, 2026 SABCS presentation will provide updated Phase 1 data. If those results support efficacy, Iksuda and LigaChem would need to initiate and complete a Phase 2 or Phase 3 trial before seeking regulatory approval. That process typically takes several years. Patients interested in current trial availability can find eligibility at NCT05872295, including open enrollment sites and current criteria.

Is IKS014 currently in trials for other cancers besides breast cancer?

Yes. IKS014 has shown early activity in HER2-positive gastroesophageal cancers in Phase 1. At ASCO GI 2026, Iksuda reported 50% ORR in esophageal cancer patients — including one complete response — across 10 evaluable HER2-positive tumors. The drug’s mechanism targets HER2 across cancer types, and the Phase 1 trial includes patients with multiple HER2-expressing solid tumors. Whether IKS014 will be developed as a priority in breast cancer, gastroesophageal cancer, or both will likely depend on how the SABCS data develops and on the company’s regulatory strategy.